Biotech Values

[DFRAI]

Anavex

Thank you Peter. I get that they used a different mouse model...and i cannot comment on its merits as i do not know the difference...however
I have attached a link to another poster of study done with transgenic AD model...see below
http://www.anavex.com/my_uploads/Chronic-Treatment-with-the-Tetrahydrofuran.pdf although conclusions of this study places a question mark i think if i read it correctly

Did you get a chance to read msg 211516? Anavex is in clinical trial for AD and has posted results of its 57 weeks. Additionally - they have just been issued a patent for combo with donepezil which enhances the results...synergistic effect

These are mono results of 57 weeks (clinical)

George Perry, PhD, Dean and Professor at the University of Texas at San Antonio and Editor-in Chief of the Journal of Alzheimer’s Disease, commented, “In addition to the very encouraging results, which point to the therapeutic potential of targeting cellular homeostasis in a complex CNS disease like Alzheimer’s, this trial has been intelligently designed as a highly informative study, looking unprejudiced at all potential relationships and hence allowing to learn from all correlations of the now available pool of data, in order to execute subsequent trials with much more relevant information at hand.”

Despite non-optimized dosing of ANAVEX 2-73 throughout the 12-month study, continued significant improvements from baseline of cognitive, functional and behavioral scores in a group of patients were observed, respectively. This data will be analyzed using refined mathematical modeling methods in conjunction with the detailed pharmacokinetic (PK) information.

Combo with donepezil (pre0clinical)
The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

Their A-371 aka AF710B is much more potent
http://www.anavex.com/pdf/2014-07-13_Fisher_Abstract_for_AAIC_meeting_2014.pdf

http://www.anavex.com/anavex-presents-new-data-on-preclinical-development-of-anavex-3-71/
The poster, titled “AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP rats,” was presented at the 14th International Symposium on Advances in Alzheimer’s Therapy (AAT) from March 9-12, 2016. The study examined the responses of ANAVEX 3-71 in aged transgenic McGill-R-Thy1-APP rats and wild-type rats dosed with 10 micrograms/kg/day ANAVEX 3-71. Both types of rats (12-14 months of age) were given either oral ANAVEX 3-71 or a placebo control for 4.5 months and then subjected to a washout period for five weeks. Following the washout, a number of cognitive tests were performed with the rats, now 18-20 months of age.
Despite the treatment interruption, the effects of administration of ANAVEX 3-71 resulted in a statistically significant improvement in cognitive function assessed by Novel Object Recognition and Morris Water Maze. In the Novel Object Recognition task, ANAVEX 3-71 completely reversed the deficit observed in transgenic rats (p<0.001), which performed similarly to wild-type rats. In the Morris Water Maze task, treated transgenic rats also fully recovered to perform at a level comparable to that of wild-type rats (p<0.001). A statistically significant reduction (p<0.05) in two measures of amyloid-beta pathology commonly associated with Alzheimer’s disease was also observed in comparison to control. Additionally, ANAVEX 3-71 demonstrated anti-inflammatory properties, compared to control (p<0.05), which may also have relevance in Alzheimer’s disease.

I really think they got something going here...of course i could be totally wrong...sigh. I will try to refrain from posting on this company. Thank you for you time.